174 related articles for article (PubMed ID: 7491817)
1. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
[TBL] [Abstract][Full Text] [Related]
2. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
[TBL] [Abstract][Full Text] [Related]
3. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
[TBL] [Abstract][Full Text] [Related]
4. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.
Tristram DA; Welliver RC; Hogerman DA; Hildreth SW; Paradiso P
Vaccine; 1994 May; 12(6):551-6. PubMed ID: 8036830
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
Groothuis JR; King SJ; Hogerman DA; Paradiso PR; Simoes EA
J Infect Dis; 1998 Feb; 177(2):467-9. PubMed ID: 9466539
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR
Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
[TBL] [Abstract][Full Text] [Related]
8. Protection against respiratory syncytial virus infection by DNA immunization.
Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
[TBL] [Abstract][Full Text] [Related]
9. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus.
Hancock GE; Smith JD; Heers KM
J Infect Dis; 2000 May; 181(5):1768-71. PubMed ID: 10823781
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
Murphy BR; Prince GA; Walsh EE; Kim HW; Parrott RH; Hemming VG; Rodriguez WJ; Chanock RM
J Clin Microbiol; 1986 Aug; 24(2):197-202. PubMed ID: 3755730
[TBL] [Abstract][Full Text] [Related]
11. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
Piedra PA; Cron SG; Jewell A; Hamblett N; McBride R; Palacio MA; Ginsberg R; Oermann CM; Hiatt PW;
Vaccine; 2003 Jun; 21(19-20):2448-60. PubMed ID: 12744878
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.
Falsey AR; Walsh EE
Vaccine; 1997 Jul; 15(10):1130-2. PubMed ID: 9269057
[TBL] [Abstract][Full Text] [Related]
14. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
[TBL] [Abstract][Full Text] [Related]
15. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
17. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.
Tristram DA; Welliver RC; Mohar CK; Hogerman DA; Hildreth SW; Paradiso P
J Infect Dis; 1993 Jan; 167(1):191-5. PubMed ID: 8418166
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
Belshe RB; Anderson EL; Walsh EE
J Infect Dis; 1993 Oct; 168(4):1024-9. PubMed ID: 8376814
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
